{"url_path":"/sec/ctor/8-k/2026-05-15/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1851484/0001213900-26-057883-index.html","accession_number":"0001213900-26-057883","cik":"0001851484","ticker":"CTOR","issuer_name":"CITIUS ONCOLOGY, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1851484/0001213900-26-057883-index.html","primary_entity_key":"0001851484","primary_entity_name":"CITIUS ONCOLOGY, INC."},"word_count":295,"has_tables":true,"body_markdown":"false\n0001851484\n\n0001851484\n\n2026-05-15\n2026-05-15\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n** **\n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n** **\n\n**FORM 8-K**\n\n** **\n\nCURRENT REPORT\n\nPursuant to Section 13 or 15(d) of\n\nthe Securities Exchange Act of 1934\n\n \n\nDate of Report (Date of earliest event reported)\n**May 15, 2026**\n\n \n\n**Citius Oncology, Inc.**\n\n(Exact name of registrant as specified in its charter)\n\n \n\n**Delaware**\n\n(State or other jurisdiction of incorporation)\n\n \n\n**001-41534**\n \n**99-4362660**\n\n(Commission File Number)\n \n(IRS Employer\n\nIdentification No.)\n\n \n\n**11 Commerce Drive, 1st Floor, Cranford, NJ**\n \n**07016**\n\n(Address of principal executive offices)\n \n(Zip Code)\n\n \n\nRegistrant’s telephone number, including\narea code **(908) 967-6677**\n\n \n\nCheck the appropriate box below if the Form 8-K filing is intended\nto simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n \n\n☐\nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n☐\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n☐\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n☐\nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\n**Title of each class**\n \n**Trading Symbol(s)**\n \n**Name of each exchange on which registered**\n\n**Common Stock**\n \n**CTOR**\n \n**The Nasdaq Capital Market**\n\n \n\nIndicate by check mark whether the registrant is an emerging growth\ncompany as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange\nAct of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging growth company ☒\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant\nhas elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant\nto Section 13(a) of the Exchange Act. ☐"}